The 24th Annual Dr. Arthur E. Iwersen Pediatric Symposium: Understanding Orofacial Myofunctional Disorders: Looking Beyond the Structure - Part 2
Thursday, April 11
2 - 5 PM
3 CDE Credits – DDS, DH, DA
ABOUT THE COURSE
In the second part of this course, participants will learn how to identify an orofacial myofunctional disorder in the dental office and how early intervention impacts healthy development of the mouth. Tools on how to screen for underlying OMD’s, identify ankyloglossia, and sleep disordered breathing will be provided. Discussion on building a multi-disciplinary collaborative approach to intervention provides success.
This session will enable participants to:
- Identify symptoms of an orofacial myofunctional disorder
- Facilitate an understanding of a growth guidance approach to dentofacial development
- Learn how to incorporate screening for oral myofunctional disorders in your patients
- Identify signs and symptoms of ankyloglossia in the dental chair
- Acquire screening tools to identify symptoms of sleep disordered breathing/OSA in the dental office
- Understand the importance of multi-disciplinary approach to successful treatment
Mary Billings, M.S., C.C.C., COM
Mary Billings, MS,CCC,COM® is a speech-language pathologist and a Certified Orofacial Myologist. She is the owner of Billings Speech Pathology Services, LLC, a private practice serving the greater Kansas City metropolitan area since 1994.
She an accredited continuing education instructor in the field of orofacial myofunctional disorders and currently serves as a Board Director for the Oral Motor Institute. She is a past President of the International Association of Orofacial Myology. In 2017, Mary was nationally recognized as a Subject Matter Expert (SME) in the area of Orofacial Myofunctional Disorders by the American Speech Language Hearing Association. Working collaboratively with other leaders in the field she has received numerous awards for her efforts to expand clinical understanding of OMDs and advocacy for early identification and treatment. Conflict of Interest: None reported